Salwa Hindawi BLOOD TRANSFUSION SUPPORT IN STEM CELL TRANSPLANT Salwa Hindawi Director of Blood...
-
Upload
jack-pierce -
Category
Documents
-
view
217 -
download
0
Transcript of Salwa Hindawi BLOOD TRANSFUSION SUPPORT IN STEM CELL TRANSPLANT Salwa Hindawi Director of Blood...
Salwa Hindawi
BLOOD TRANSFUSION SUPPORT IN STEM CELL
TRANSPLANT
Salwa HindawiDirector of Blood Transfusion Services
KAUH, Jeddah Saudi Arabia
Salwa Hindawi
Introduction
Bone Marrow Transplant can be either: Allogeneic Autologous PBSCT Cord Blood
Salwa Hindawi
Diseases Treatable by BMT
· Non-Hodgkin's Lymphoma· Hodgkin’s Disease· Multiple Myeloma· Acute Leukemias· Chronic Leukemias· Myelodysplasia· Testicular Cancer· Aplastic Anemia
Salwa Hindawi
Salwa Hindawi
Basic transplant issues that impact Basic transplant issues that impact blood bank policies.blood bank policies.
Recognize common serologic problems Recognize common serologic problems encountered in transplant recipientsencountered in transplant recipients
Appropriate blood products when Appropriate blood products when transfusion is needed.transfusion is needed.
Role of transfusion servicesRole of transfusion services
Salwa Hindawi
Basic transplant issues
Recipient-Donor ABO compatibility.Recipient-Donor ABO compatibility.
ABO and Rh compatibility are not required ABO and Rh compatibility are not required for the successful outcome of BMTfor the successful outcome of BMT
Salwa Hindawi
BASIC TRANSPLANT ISSUES
Special Blood Requirement
• Irradiated• CMV Negative• Leukocyte-Reduced• Saline-washed or volume reduced
Salwa Hindawi
Is this a major or minor ABO incompatibility? How high the patient’s antibody titers against
the donor’s ABO group? How high the donor’s antibody titers against
the patient’s ABO group? Will the patient require special conditioning?
Will the HPC collection require processing?
Pre-Transplant Considerations
Salwa Hindawi
Compatible transplantCompatible transplant
Immunohemtologic complicationsImmunohemtologic complications
Major incompatibility Major incompatibility Minor incompatibilityMinor incompatibilityMajor & minor incompatibilityMajor & minor incompatibility
RECIPIENT-DONOR ABO COMPATIBILITYRECIPIENT-DONOR ABO COMPATIBILITY
Salwa Hindawi
Recipient- Donor ABO Compatibility
ABO Major Mismatch: Recipient is O-Donor is A
-Acute hemolysis at infusion. -Delayed hemolysis from persistent patient
antibodies. -Delayed onset of hematopoiesis.
ABO Minor Mismatch: Recipient is A- Donor is O
-Acute hemolysis at infusion. -Delayed hemolysis from donor antibodies.
ABO Major-Minor Mismatch: Recipient is A-Donor is B
Salwa Hindawi
Blood Group O A B AB
O Compatible Major Major Major
A Minor Compatible Major and minor
Major
B Minor Major and minor
Compatible Major
AB Minor Minor Minor Compatible
RE
CIP
IEN
T
ABO COMPATIBILITYDONOR
Salwa Hindawi
TRANSFUSIONS FOLLOWING BONE MARROW TRANSPLANTATION
beginning with preparative regimen
ABO compatibility is not required between bone marrow donor and recipient.
Compatible transplant no special requirements Minor incompatibility recipient type plasma and platelet until
recipient cells have disappeared
Salwa Hindawi
TRANSFUSIONS FOLLOWING BONE MARROW TRANSPLANTATION
Major incompatibility recipient type red cells until recipient
isoagglutinins have disappeared Major and minor incompatibilities group AB plasma, group AB or washed
platelets until recipient cells gone; group O red cells until recipient isoagglutinins have disapeared.
Salwa Hindawi
Patient ABO
Donor ABO
RBCFFP
1st Choice plt2nd Choice plt
OAB
AB
OOO
A,ABB,ABAB
B,OA,O
A,B,O
AOB
AB
OO
A,O
A,ABABAB
B,OB,A,OA,B,O
BOA
AB
OO
B,O
B,ABABAB
A,OA,B,OB,A,O
ABOAB
OA,OB,O
ABABAB
A,B,OA,B,OA,B,O
Blood Selection when recipient/donor are not ABO identical
Salwa Hindawi
major Rh-incomp.,patient anti-D antibodies against engrafted donor Rh+ RBCs.
Mismatches involving Rh system may cause hemolysis, do not affect survival.
Kidd,M,N and S.
NON-ABO MISMATCHES
Salwa Hindawi
Complications Related to Blood Transfusion
Haemolysis
Alloimmunization to red cell antigens
Infection (CMV)
Graft-Verses Host Disease (GVHD)
Salwa Hindawi
Delayed hemolysis 7-14 days post transplant
Mediated by donor lymphocytes carried in the HSC component
Immune hemolysis of the recipient’s red cells as results of anti A and/or anti B production
PBSC at greater risk than marrow Abrupt onset may be severe with signs of
IV hemolysis
Passenger B lymphocyte syndrome
Salwa Hindawi
Worsen with transfusion ,due to hemolysis of transfused group O RBCs .
Methotrexate as anti-proliferative agent use to suppress the proliferation of donor lymphocytes in HSC inoculum.
Passenger B lymphocyte syndrome
Salwa Hindawi
Transfusion of Group O red cells Occasional red cell exchange transfusion
is indicated to replace the recipient’s incompatible red cells with Group O.
Recipient ABO plts type
PROPHYLAXIS
Salwa Hindawi
Red cell depletion and/or plasma depletion ONLY performed on BM collection.
Red cell depletion: Recipient has Ab against Donor red cells.
To avoid hemolysis of donor red blood cells in HPC collection.
Plasma depletion: Donor has AbS against Recipient red cell .
To avoid hemolysis of red blood cells in recipient’s circulation.
Marrow Processing
Salwa Hindawi
Alloimmunization
Prevention of Febrile Non Haemolytic Transfusion Reaction.
Replacement of CMV negative blood components.
Leucodepletion of Blood Components
Salwa Hindawi
Irradiation of blood products
All cellular components should be gamma irradiated (25 Gy or 2500 cGy) this inactivates the T lymphocytes in the donor unit and prevents graft versus host disease in an immunocompromised recipient.
Start at conditioning for 6month in Allogeneic BMT 3 month for Autologous BMT
Salwa Hindawi
Indications for Gamma Irradiated Blood Components
congenital immunodeficiency syndromes. intrauterine transfusions. All neonates who received intrauterine
transfusion. transfusions from all blood relatives. bone marrow transplant recipients.
Salwa Hindawi
Cord Blood The multipotent-stem-cell-rich blood found in the
umbilical cord has proven useful in treating the same types of diseases as those treated using bone marrow stem cells and PBSCs.
Umbilical cord blood stem cell transplants are less prone to rejection than either bone marrow or
peripheral blood stem cells. Umbilical cord blood lacks well-developed immune
cells
the cells have not yet developed the features that can be recognized and attacked by the
recipient's immune system
Salwa Hindawi
Conclusions: Bone marrow transplantation (BMT) is rapidly
expanding as a practical and therapeutic modalities.
the transfusion medicine professional must take into account the series of immunohematological changes and complications that may arise in such patients.
We must apply techniques, methods, and approaches not routinely used in the general blood-banking environment.
Salwa Hindawi